Sign in →

Test ID LMPP Lipoprotein Metabolism Profile, Serum

Reporting Name

Lipoprotein Metabolism Profile

Useful For

Diagnosing dyslipoproteinemia

 

Quantitation of cholesterol and triglycerides in very-low-density lipoprotein, low-density lipoprotein (LDL), high-density lipoproteins (HDL), and chylomicrons

 

Identification of LpX

 

Classifying hyperlipoproteinemias (lipoprotein phenotyping)

 

Evaluating patients with abnormal lipid values (cholesterol, triglyceride, HDL, LDL) for specific phenotypes

 

Quantifying lipoprotein a cholesterol

Profile Information

Test ID Reporting Name Available Separately Always Performed
TCS Cholesterol, Total, CDC, S No Yes
TRIGC Triglycerides, CDC, S No Yes
APLBS Apolipoprotein B, S No Yes
HDLS HDL Cholesterol, CDC, S No Yes
LMPP1 Lipoprotein Metabolism Profile 1 No Yes

Specimen Type

Serum


Necessary Information


Patient's age and sex are required.



Specimen Required


Patient Preparation:

1. Fasting-overnight (12-14 hours)

2. Patient must not consume any alcohol for 24 hours before the specimen is collected.

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 5 mL


Specimen Minimum Volume

2 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  60 days

Reference Values

2-9 years

10-17 years

≥18 years

Total cholesterol

*

Acceptable: <170 mg/dL

Borderline high: 170-199 mg/dL

High: ≥200 mg/dL

**

Desirable: <200 mg/dL

Borderline high: 200-239 mg/dL

High: ≥ 240 mg/dL

Triglycerides

*

Acceptable: <75 mg/dL

Borderline high: 75-99 mg/dL

High: ≥100 mg/dL

*

Acceptable: <90 mg/dL

Borderline high: 90-129 mg/dL

High: ≥130 mg/dL

**

Normal: <150 mg/dL

Borderline high: 150-199 mg/dL

High: 200-499 mg/dL

Very high: ≥500 mg/dL

Low-density lipoprotein (LDL) cholesterol

*

Acceptable: <110 mg/dL

Borderline high: 110-129 mg/dL

High: ≥130 mg/dL

***

Desirable: <100 mg/dL

Above Desirable: 100-129 mg/dL

Borderline high: 130-159 mg/dL

High: 160-189 mg/dL

Very high: ≥190 mg/dL

LDL triglycerides

≤50 mg/dL

≤50 mg/dL

Apolipoprotein B

*

Acceptable: <90 mg/dL

Borderline high: 90-109 mg/dL

High: ≥110 mg/dL

***

Desirable: <90 mg/dL

Above Desirable: 90-99mg/dL

Borderline high: 100-119 mg/dL

High: 120-139 mg/dL

Very high: ≥140 mg/dL

High-density lipoprotein (HDL) cholesterol

*

Low: <40 mg/dL

Borderline low: 40-45 mg/dL

Acceptable: >45 mg/dL

***

Males: ≥40mg/dL

Females: ≥50mg/dL

 

Very low-density lipoprotein (VLDL) cholesterol

<30 mg/dL

<30 mg/dL

VLDL triglycerides

<90 mg/dL

<120 mg/dL

Beta VLDL cholesterol

<15 mg/dL

<15 mg/dL

Beta VLDL

triglycerides

<15 mg/dL

<15 mg/dL

Chylomicron cholesterol

Undetectable

Undetectable

Chylomicron triglycerides

Undetectable

Undetectable

Lp(a) cholesterol

<5 mg/dL

<5 mg/dL

LpX

Undetectable

Undetectable

 

Reference values have not been established for patients who are less than 2 years of age.

*Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents

**National Cholesterol Education Program (NCEP)

***National Lipid Association

Day(s) Performed

Monday through Thursday, Sunday

CPT Code Information

80061-Lipid panel (includes: HDL [CPT Code 83718], total cholesterol [CPT Code 82465], and triglycerides [CPT Code 84478])

82172-Apolipoprotein B

83700-Lp(a) cholesterol electrophoresis

LOINC Code Information

Test ID Test Order Name Order LOINC Value
LMPP Lipoprotein Metabolism Profile In Process

 

Result ID Test Result Name Result LOINC Value
TCS Cholesterol, Total, CDC, S 2093-3
HDLS HDL Cholesterol, CDC, S 2085-9
TRIGC Triglycerides, CDC, S 2571-8
APLBS Apolipoprotein B, S 1884-6
2839 LDL Cholesterol 2089-1
2840 LDL Triglycerides 3046-0
2844 VLDL cholesterol 2091-7
2847 VLDL triglycerides 3047-8
2842 Beta VLDL Cholesterol 66499-5
2843 Beta VLDL triglycerides 3045-2
2855 Chylomicron cholesterol 34467-1
2856 Chylomicron triglycerides 35363-1
2849 Lp(a) Cholesterol 35388-8
23924 LpX 42178-4
23937 Interpretation 59462-2

Clinical Information

Lipoprotein metabolism profile analysis adds practical information about the etiology of cholesterol and/or triglyceride elevation. In some patients, increased serum lipids reflect elevated levels of intermediate-density lipoprotein, very-low-density lipoprotein, lipoprotein a (Lp[a]), or even the abnormal lipoprotein complex, LpX. These elevations can be indicative of a genetic deficiency in lipid metabolism or transport, nephrotic syndrome, endocrine dysfunction, or even cholestasis. Identification of the lipoprotein associated with lipid elevation is achieved using the gold-standard methods, which include ultracentrifugation, selective precipitation, electrophoresis, and direct measurement of cholesterol and triglycerides in isolated lipoprotein fractions. Proper characterization of a patient's dyslipidemic phenotype aids clinical decisions and guides appropriate therapy.

 

Classifying the hyperlipoproteinemias into phenotypes places disorders that affect plasma lipid and lipoprotein concentrations into convenient groups for evaluation and treatment. A clear distinction must be made between primary (inherited) and secondary (liver disease, alcoholism, metabolic diseases) causes of dyslipoproteinemia. Lipoprotein profiling will identify the presence of Lp(a) and LpX and distinguish between the following dyslipidemias:

-Exogenous hyperlipemia (Type I)

-Familial hypercholesterolemia (Type IIa)

-Familial combined hyperlipidemia (Type IIb)

-Familial dysbetalipoproteinemia (Type III)

-Endogenous hyperlipemia (Type IV)

-Mixed hyperlipemia (Type V)

Interpretation

Patients with increased lipoprotein a (Lp[a]) cholesterol values have been associated with increased risk for the development of atherothrombotic disease. Aggressive LDL reduction is the recommended treatment approach in most patients with increased Lp(a).

 

Lipoprotein-X (LpX) is an abnormal lipoprotein that appears in the sera of patients with obstructive jaundice and is an indicator of cholestasis. The presence of LpX will be reported if noted during Lp(a) cholesterol analysis.

Clinical Reference

1. Grundy SM, Stone NJ, Bailey AL, et al: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019 Jun 18;139(25):e1082-e1143

2. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute: Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011 Dec;128 Suppl 5:S213-S256

3. Rosenson RS, Najera SD, Hegele RA: Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome. J Clin Lipidol. 2017 Jan-Feb;11(1):294-296. doi: 10.1016/j.jacl.2016.12.005

4. Hopkins PN, Brinton EA, Nanjee MN: Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep. 2014 Sep;16(9):440. doi: 10.1007/s11883-014-0440-2

5. Gotoda T, Shirai K, Ohta T, et al: Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19(1):1-12

6. Gonzales KM, Donato LJ, Shah P, Simha V: Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis. J Clin Lipidol. 2021 Jan-Feb;15(1):97-103. doi: 10.1016/j.jacl.2020.11.010

7. Fatica EM, Meeusen JW, Vasile VC, Jaffe AS, Donato LJ: Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. Clin Biochem. 2020 Dec;86:45-51. doi: 10.1016/j.clinbiochem.2020.09.007

8. Arnett DK, Blumenthal RS, Albert MA, et al: 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Sep 10;140(11):e596-e646

Report Available

2 to 4 days

Method Name

Ultracentrifugation/Electrophoresis/Automated Enzymatic/Colorimetric Analysis

Forms

If not ordering electronically, complete, print, and send a Cardiovascular Test Request (T724) with the specimen.

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.